Esperion Therapeutics Inc. says it has FDA's blessing to use the 505(b)2 pathway to submit a combination of its cholesterol drug bempedoic acid with Merck & Co. Inc.'s Zetia (ezetimibe), referencing both Zetia and a parallel NDA for bempedoic acid.
Bempedoic acid inhibits ATP citrate lyase, an enzyme on the cholesterol biosynthesis pathway, and is part of a wave of...





